Why Is DAMORA THERAPEUTICS (DMRA) Stock Up Today?

Why DMRA stock is up today

Damora Therapeutics stock rose 7.29% to $30.04 in afternoon trading on September 4, 2026. The move followed the company’s announcement of inducement equity awards to three newly hired, non-executive employees on September 1. The stock opened with a 1.8% gap down but recovered to a session high of $30.04 as the day progressed.

What Happened

Damora Therapeutics disclosed on September 1 that it issued inducement grants under Nasdaq Listing Rule 5635(c)(4). The move is typically used to attract new talent by offering stock-based compensation. The announcement came amid a broader backdrop of recent developments for the biotech firm. Earlier in the year, Damora Therapeutics initiated the Phase 1/1b CLARITY-101 study of its drug candidate DMR-001 for patients with Mutcalr-driven essential thrombocythemia and myelofibrosis. Additionally, Wedbush recently raised its price target for the stock to $40 and maintained an Outperform rating.

What The Data Shows

The stock opened at $27.49 and traded as low as $27.39 before rallying to $30.04 by the close. The session saw 0.1 million shares traded, which is 0.3 times the 3-month daily average. The stock has a market capitalization of $1.7 billion and remains unprofitable with a trailing twelve-month EPS of -9.88. It has a beta of 1.48, indicating higher volatility than the broader market. The stock’s 52-week range is $2.45 to $38.33, and it printed one fresh 52-week low on the same day it hit 25 fresh 52-week highs.

What To Watch

Damora Therapeutics is not scheduled to report earnings in the near term. Investors may look to monitor the breadth of coverage and any further updates from the ongoing CLARITY-101 study, as well as Wedbush’s continued Outperform stance.